Signal active
Bio
Fred Craves, PhD, is an Investment Partner, Managing Director and Founder of Bay City Capital, and serves as a member of the board of directors and Chairman of the executive committee. Before founding Bay City Capital, he spent over 20 years leading and managing biotechnology and pharmaceutical companies. Previously, he was Executive Vice President of Schering Berlin and Chief Executive Officer and President of Berlex Biosciences, a research, development, and manufacturing organization. He founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. He was also the founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. Dr. Craves is a member of the boards of directors of Poniard Pharmaceuticals, Dermira, Madrigal Pharmaceuticals and Reset Therapeutics. He also serves as a member of The J. David Gladstone Institutes' Advisory Council and is a member of the Board of Trustees of Loyola Marymount University in Los Angeles. Dr. Craves earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco.
Location
San Francisco, California, United States, North America
Social
Primary Organization
1997
131
25
63
11-50
Biotechnology
Jobs history
1
Board Member
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Fred Craves is the Managing Director at Bay City Capital, based in United States, North America. With a background in Biotechnology, Fred Craves has a rich history of leadership and innovation. Fred Craves studied BS Biology @ Georgetown University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
4
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Mar 05, 2010 | Ion Torrent | Series C - Ion Torrent | Bay City Capital | 37.1M |
Jun 11, 2013 | Dermira | Series B - Dermira | Bay City Capital | 35.0M |
Aug 19, 2014 | Dermira | Series C - Dermira | Bay City Capital | 51.0M |
Jan 05, 2018 | - | Series A - KBP Biosciences | Bay City Capital | 76.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.